课题基金 / 基金详情

HOMOCYSTEINE MODIFIES BONE MATRIX AND MINERALIZATION

HOMOCYSTEINE MODIFIES BONE MATRIX AND MINERALIZATION
同型半胱氨酸改变骨基质和矿化
批准号:
7229902
负责人:
CHARLES W PRINCE
金额:
$14.48万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-02-15 至 2009-01-31

项目摘要

项目成果

CHARLES W PRINCE的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):几年前我们假设,中等水平的高同型半胱氨酸血症可能在一些通常被认为是衰老的正常后果的结缔组织病理中起到因果作用。我们强调了同型半胱氨酸尿症(血清同型半胱氨酸浓度通常为>100(m/L))的标志性表现之间的相似之处,即闭塞性血管疾病、骨质疏松、智力恶化和异位晶状体,以及“正常”衰老(血清同型半胱氨酸浓度在10到100(m/L)之间)的相应表现之间的相似之处,即闭塞性血管疾病、骨质疏松症、痴呆和老花眼。重要的是要认识到,这些同型半胱氨酸(Hcy)升高的表现通常是浓度和年龄相关的,即高同型半胱氨酸血症越严重,发病年龄越早。例如,在15岁以前未经治疗的同型半胱氨酸尿症患者中,有40%的人可以通过X光片检测到骨质疏松,而在30岁之前,这一比例为80%。相反,中度高同型半胱氨酸血症应该需要长时间的暴露才能产生类似的病理。因此,关于骨骼,我们假设,长期、适度升高的同型半胱氨酸在与衰老相关的骨质疏松症的发展中具有因果作用。在这项发展赠款中,我们寻求资金,为我们的主要假设基础上的一些假设建立实验原则证明。我们假设1)同型半胱氨酸和/或同型半胱氨酸介导的骨细胞外基质蛋白在体内发生改变,以及2)同型半胱氨酸和/或同型半胱氨酸在体外可以损害成骨细胞的骨形成。为了验证这些假设,我们制定了以下各自的具体目标:1)在这一应用中,我们试图从人类骨骼中分离Hcy或Hcytl修饰的蛋白质,并在可能的情况下对它们进行鉴定。我们将检查皮质骨和松质骨,并试图确定这两种类型的人骨中与蛋白质相关的同型半胱氨酸之间是否存在年龄相关的关联。为了更好地理解这种翻译后修饰的化学,我们还将实验研究导致Hcy并入骨基质蛋白的条件。2)建立人骨髓基质细胞培养体系,诱导成骨细胞分化,观察Hcy和Hcytl升高对细胞增殖率、细胞外基质形成、成骨细胞分化程度和基质矿化的影响。我们还将检查Hcy或Hcytl改变预先形成的成骨细胞来源的基质矿化程度的能力。这些研究应该提供有关骨质疏松症可能机制的新数据,并为治疗和预防提出新的治疗方法。
英文摘要
DESCRIPTION (provided by applicant): We hypothesized several years ago that moderate levels of hyperhomocysteinemia may have a causal role in a number of connective tissue pathologies typically thought of as normal consequences of aging. We emphasized the parallels between the hallmark manifestations of homocystinuria (with serum homocysteine concentrations typically >100 (m/L), ie, occlusive vascular disease, osteoporosis, mental deterioration, and ectopia lentis, and the counterpart manifestations of "normal" aging (with serum homocysteine concentrations between 10 and 100 (m/L), ie, occlusive vascular disease, osteoporosis, dementia, and presbyopia. It is important to recognize that these manifestations of elevated homocysteine (Hcy) are generally concentration and age-dependent, i.e., the more severe the hyperhomocysteinemia, the younger the age of onset. For example, osteoporosis is detectable by radiographs in 40% of untreated homocystinuric patients by age 15 and in 80% by age 30. Conversely, moderate hyperhomocysteinemia should require prolonged periods of exposure to produce similar pathology. Thus, with regard to bone, we hypothesize that prolonged, moderately elevatated homocysteine has a causal role in the development of the osteoporosis associated with aging. In this developmental grant we seek funding to establish experimental proof of principle for some of the assumptions underlying our main hypothesis. We HYPOTHESIZE that 1) Hcy- and/or Hcytl-mediated alterations of bone extracellular matrix proteins occur in vivo, and that 2) Hcy and/or Hcytl can impair bone formation by osteoblasts in vitro. To test these hypotheses, we have developed the following respective SPECIFIC AIMS: 1) In this application we seek to isolate proteins from human bone that are modified with Hcy or Hcytl and identify them, if possible. We will examine both cortical and cancellous bone and seek to determine if there is an age-related association between protein-associated Hcy in both types of human bone. In order to better understand the chemistry of this post- translational modification, we will also experiment investigate conditions that result in the incorporation of Hcy into bone matrix proteins. 2) We will establish human bone marrow stromal cell cultures, induce osteoblast differentiation, and evaluate the effects of elevated Hcy and Hcytl on rates of cell proliferation, extracellular matrix formation, extent of osteoblast differentiation and matrix mineralization. We shall also examine the ability of Hcy or Hcytl to alter the extent of mineralization of pre-formed osteoblast-derived matrices. These studies should provide new data regarding possible mechanisms of osteoporosis as well as suggest new therapies for treatment and prevention.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HOMOCYSTEINE MODIFIES BONE MATRIX AND MINERALIZATION
Homocysteine's role in the causation of presbyopia
HOMOCYSTEINEMIA--A RISK FACTOR FOR OSTEOPOROSIS
HOMOCYSTEINEMIA--A RISK FACTOR FOR OSTEOPOROSIS
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
  • 批准号:
    82505677
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.00万元
  • 批准年份:
    2025
  • 负责人:
    吕雨霏
  • 依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
  • 批准号:
    82574874
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2025
  • 负责人:
    刘天华
  • 依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位: